Financing - May 4, 2022
Finnadvance raises a 1.2 million EUR seed funding round
Finnish startup Finnadvance has secured a 1.2 million EUR seed financing round led by Finnish investor Athensmed. Several existing investors, such as deep tech VC Voima Ventures and early-stage VC Icebreaker, are participating in the funding round. In addition, the funding also includes a new investor: Takoa Invest. Finnadvance is a biotechnology start-up from Oulu, […]
CRO - May 2, 2022
Serendipity has been invited as a part owner of LINK Medical
Serendipity Partners (Serendipity) now owns 49% of the shares, however, Dr. Ola Gudmundsen will still hold the majority of the shares. The transaction is mainly structured as a share issue, where Serendipity provides growth capital to LINK Medical, states the company. Co-owners and long-term investors To enable further growth and provide new competencies to the […]
Financing - April 12, 2022
Umeå Biotech Incubator gets EU grant extension
The Swedish Agency for Economic and Regional Growth has awarded Umeå Biotech Incubator (UBI) a grant of SEK 9.5 million. For the next 18 months, Umeå Biotech Incubator (UBI) will develop meeting places and create the conditions for the continued growth of the life science industry in northern Sweden. “We are delighted that our application […]
Financing - April 12, 2022
AlzeCure Pharma carries out a set-off issue
The company is carrying out a set-off issue of 845,070 shares to Acturum Life AB as a result of a previously agreed milestone payment, which will be made in the form of shares instead of cash payment. “The set-off issue strengthens the company’s liquidity and we are pleased that Acturum Life chooses to show its […]
Financing - April 11, 2022
Moberg Pharma carries out a fully guaranteed issue
The Board of Directors of Moberg Pharma has resolved to carry out a fully guaranteed issue of new ordinary shares with preferential rights for existing shareholders of approximately SEK 121 million before transaction costs. The Rights Issue is conditional upon approval at an extraordinary general meeting, states the company. “The financing we have secured gives […]
Biotech Business - March 29, 2022
XNK Therapeutics raises 132 million SEK
The company has secured a private placement, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development in multiple myeloma and other indications. The company’s lead investigational candidate drug is currently being evaluated in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab) in […]
